Stock Events

Stock Events

Biofrontera 

€2.42
42
+€0.05+2.11% Wednesday 06:00

Statistics

Day High
2.37
Day Low
2.37
52W High
2.84
52W Low
2.21
Volume
-
Avg. Volume
-
Mkt Cap
28.19M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.93
-0.48
-0.03
0.41
Expected EPS
-0.09990395
Actual EPS
N/A

Financials

-47.24%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
70.93MRevenue
-33.51MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow B8FK.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Davis Select U.S. Equity
DUSA
Mkt Cap0
DUSA Pharmaceuticals, Inc. is a direct competitor in the dermatology space, specifically in photodynamic therapy products, similar to Biofrontera's Ameluz for treating actinic keratosis.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. has a diversified portfolio that includes treatments for various conditions, including skin-related diseases, potentially competing with Biofrontera's dermatological products.
Pfizer
PFE
Mkt Cap161.09B
Pfizer Inc. is a global pharmaceutical company with a broad product line that includes treatments for skin conditions, making it a competitor to Biofrontera.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson offers a wide range of healthcare products, including pharmaceuticals and personal care products for skin health, competing with Biofrontera's dermatological treatments.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie Inc., having acquired Allergan, has strengthened its dermatology portfolio, making it a stronger competitor to Biofrontera in the skin care and treatment market.
Novartis
NVS
Mkt Cap297.32B
Novartis International AG has a significant presence in the dermatology market with products that treat a range of skin conditions, competing with Biofrontera's therapeutic offerings.

About

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Show more...
CEO
ISIN
DE000A4BGGM7
WKN
000A4BGGM

Listings

XNAS
US
BFRI
XNAS
US
BFRIW
XETRA
DE
B8FK.XETRA
F
DE
B8FK.F

0 Comments

Share your thoughts

FAQ

What is Biofrontera stock price today?▼
The current price of B8FK.F is €2.42 EUR — it has increased by +2.11% in the past 24 hours. Watch Biofrontera stock price performance more closely on the chart.
What is Biofrontera stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Biofrontera stocks are traded under the ticker B8FK.F.
Is Biofrontera stock price growing?▼
B8FK.F stock has risen by +2.11% compared to the previous week, the month change is a -8.68% fall, over the last year Biofrontera has showed a -2.62% decrease.
What is Biofrontera market cap?▼
Today Biofrontera has the market capitalization of 28.19M
When is the next Biofrontera earnings date?▼
Biofrontera is going to release the next earnings report on May 08, 2026.
What were Biofrontera earnings last quarter?▼
B8FK.F earnings for the last quarter are 0.41 EUR per share, whereas the estimation was 0.17 EUR resulting in a +146.15% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Biofrontera revenue for the last year?▼
Biofrontera revenue for the last year amounts to 70.93M EUR.
What is Biofrontera net income for the last year?▼
B8FK.F net income for the last year is -33.51M EUR.
When did Biofrontera complete a stock split?▼
The last stock split for Biofrontera was on May 14, 2024 with a ratio of 1:21.